Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
24 hedge funds and large institutions have $9.77M invested in Aevi Genomic Medicine Inc in 2014 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 4 closing their positions.
11% less funds holding
Funds holding: 27 → 24 (-3)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
43% less capital invested
Capital invested by funds: $17.2M → $9.77M (-$7.41M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$160K |
| 2 |
SIM
Spark Investment Management
New York
|
+$87.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$78.9K |
| 4 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$61.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$1.26M |
| 2 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$1.14M |
| 3 |
U
UBS
Zurich,
Switzerland
|
-$24.5K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$20K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BRWA
26
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$15.5K | -2,000 | Closed |
|
27
Barclays
London,
United Kingdom
| – | -$5K | -700 | Closed |
|
28
BNP Paribas Financial Markets
Paris,
France
| – | -$2.39K | -308 | Closed |
|
GNMX Hedge Fund Activity: Q3 2014 in Review
24 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2014, worth a combined $9.77M — down 43% from $17.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GNMX and 1 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $160K. The largest seller was Legal & General Group, cutting an estimated $1.26M.
- 24 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2014, down from 27 in Q2 2014.
- Funds reported $9.77M of Aevi Genomic Medicine Inc stock for Q3 2014, down 43% quarter-over-quarter.
- 1 fund opened new Aevi Genomic Medicine Inc positions in Q3 2014 and 4 closed out, a net change of -3 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2014 was BlackRock Institutional Trust, an estimated $160K added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2014 was Legal & General Group, an estimated $1.26M sold.
Based on aggregated 13F filings for Q3 2014.